EASE TRICUSPID Expertise-based Assessment Study on Clinical Efficacy of Contour 3D® in TRICUSPID Valve Annuloplasty
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Few clinical evidence for the Contour 3D Tricuspid Annuloplasty Ring exists; therefore, in order to position this product on the market, a post-market release study will be completed. The purpose of this study is to evaluate the hemodynamic performance of the Contour 3D® Tricuspid Annuloplasty Ring following Tricuspid Valve repair in a post-market environment.
| Condition |
|---|
|
Evaluate the Hemodynamic Performance |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | EASE TRICUSPID Expertise-based Assessment Study on Clinical Efficacy of Contour 3D® in TRICUSPID Valve Annuloplasty |
- Mean Gradient across the TV [ Time Frame: discharge through 6 months post-implant ] [ Designated as safety issue: No ]The mean gradient across the TV measured via echocardiography at discharge through 6 months post-implant
| Estimated Enrollment: | 85 |
| Study Start Date: | September 2011 |
| Estimated Study Completion Date: | August 2015 |
| Estimated Primary Completion Date: | March 2015 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
indicated for a TV repair procedure
all patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for which the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.
|
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
The patient population includes all patients indicated for a TV repair procedure concomitantly to left-sided heart surgery, and for which the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve. Patients with primary TV are not included, since this is often characterized by pathological leaflets for which the Contour 3D® Tricuspid Annuloplasty Ring would not be beneficial.
Inclusion Criteria:
- Willing to sign and date the Patient Informed Consent (PIC)
- Indicated for a concomitant surgical repair of the TV
- Willing to return to the hospital, where the implantation originally occurred, for a 6 month follow-up visit
Exclusion Criteria:
- Patients with a degenerative TV condition
- Patients with primary TV regurgitation
- Previous TV repair or replacement
- Stand-alone TV repair
- Already participating in another investigational device or drug study, possibly leading to bias and jeopardizing the scientific appropriate assessment of the study endpoints
- Life expectancy of less than one year
- Pregnant or desire to be pregnant within 12 months of the study treatment
- Under 18 years or over 85 years of age
- Patients with active endocarditis
- Patients with valvular retraction with severely reduced mobility
- Patients with a heavily calcified TV
Contacts and Locations| Contact: Anneleen Daniels | +31 43 356 6789 | anneleen.daniels@medtronic.com |
| Contact: Ber Kleijnen | +31 43 356 6812 | ber.kleijnen@medtronic.com |
| Germany | |
| Deutsches Herzzentrum München | Recruiting |
| Munich, Germany, D-80636 | |
| Contact: Ralf Guenzinger, Dr. guenzinger@dhm.mhn.de | |
| Principal Investigator: | Rüdiger Lange, Prof. Dr. med. | Deutsches Herzzentrum München |
More Information
No publications provided
| Responsible Party: | Medtronic Bakken Research Center |
| ClinicalTrials.gov Identifier: | NCT01532921 History of Changes |
| Other Study ID Numbers: | EASE TRICUSPID |
| Study First Received: | February 10, 2012 |
| Last Updated: | March 23, 2013 |
| Health Authority: | Germany: Ethics Commission France: Conseil National de l'Ordre des Médecins United Kingdom: Research Ethics Committee United Kingdom: National Health Service Austria: Ethikkommission |
ClinicalTrials.gov processed this record on May 21, 2013